Comment on FR Doc # 2026-10128

Summary: Health policy economists from The Brookings Institution oppose the proposed rule, arguing that collecting more production-cycle data without addressing the underlying complexity and delays of the quota system will not reduce drug shortages. They contend that the new data may be used to tighten the system rather than build resilience and recommend reforms such as allowing quota rollover and moving toward single annual allocations.